Clinical Pharmacology and Therapeutics 2004-10-01

Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass.

Mias Pretorius, Julie A McFarlane, Douglas E Vaughan, Nancy J Brown, Laine J Murphey

Index: Clin. Pharmacol. Ther. 76(4) , 379-87, (2004)

Full Text: HTML

Abstract

This study tested the hypothesis that angiotensin-converting enzyme (ACE) inhibitors potentiate activation of the kallikrein-kinin system during cardiopulmonary bypass (CPB).The effects of CPB on concentrations of bradykinin and its metabolite bradykinin 1-5 (BK1-5) were determined in 31 patients taking an ACE inhibitor who were randomized to continue ACE inhibitors until coronary artery bypass surgery (ACE inhibitor group, N = 19) or to discontinue them 48 hours before surgery (no ACE inhibitor group, N = 12). Arterial and venous blood was sampled before CPB, at 30 minutes of CPB, at 60 minutes of CPB, after separation from CPB, and on postoperative day 1.Arterial bradykinin ( P < .001 [from 22.4 +/- 24.1 fmol/mL to 86.2 +/- 98.7 fmol/mL in the no ACE inhibitor group]) and arterial ( P < .001) and venous ( P = .016) BK1-5 concentrations increased significantly during CPB. Arterial bradykinin concentrations were significantly higher ( P = .017), whereas BK1-5 concentrations ( P = .024) and the molar ratio of BK1-5/bradykinin ( P = .008) were significantly lower in the ACE inhibitor group compared with the no ACE inhibitor group. In addition, arterial bradykinin concentrations were significantly increased in smokers compared with nonsmokers ( P = .015), when we controlled for the ACE inhibitor group. There was no effect of smoking on ACE activity ( P = .597 overall). There was a significant inverse correlation between arterial bradykinin and mean arterial pressure ( r 2 = 0.2137, P = .010) and a significant correlation between arterial bradykinin and tissue-type plasminogen activator antigen concentrations ( r 2 = 0.174, P = .022) during CPB. Tissue-type plasminogen activator antigen was significantly higher in the ACE inhibitor group than in the no ACE inhibitor group (18.0 +/- 7.8 ng/mL versus 12.4 +/- 4.5 ng/mL, P = .016) but not in smokers compared with nonsmokers ( P = .451).Preoperative ACE inhibitors and smoking potentiate the kinin response to CPB and may contribute to the hemodynamic and fibrinolytic response observed during CPB.


Related Compounds

Related Articles:

Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries.

2001-11-01

[Thromb. Haemost. 86(5) , 1296-304, (2001)]

Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.

2008-05-01

[J. Thromb. Haemost. 6(5) , 837-45, (2008)]

Bradykinin metabolism in rat hind limbs.

1998-08-01

[Shock 10(2) , 146-52, (1998)]

Oral thrombostatin FM19 inhibits prostate cancer.

2010-11-01

[Thromb. Haemost. 104(5) , 1044-8, (2010)]

Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4.

2005-01-03

[FEBS Lett. 579(1) , 25-9, (2005)]

More Articles...